GlassScriptPhysician profile
Christine M Dobrasz
NPI 1205186145
$8,236.21
in general payments reported to CMS, 2019-2025
26 companies · $2,067 in 2025
The $2,067 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,011 · 2022: $1,940 · 2023: $1,810 · 2024: $1,408 · 2025: $2,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,088 · Education: $172 · Consulting Fee: $25.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,087.72 |
| Education | $171.87 |
| Consulting Fee | $25.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,294.16 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,614.02 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,179.71 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $673.52 | 2023-2025 | |
| Amgen INC. | $584.35 | 2021-2025 | Tezspire |
| Optinose US, INC. | $281.81 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $236.61 | 2021-2025 | Cuvitru, Eohilia, Hyqvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.97 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Kaleo, INC. | $195.16 | 2021-2024 | Auvi-Q |
| Alk-Abello, INC | $188.27 | 2021-2025 | Odactra, Ragwitek, Grastek |
| Biocryst US Sales Co., LLC | $122.22 | 2022-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $102.52 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $88.98 | 2021-2022 | |
| Insulet Corporation | $71.50 | 2024-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $66.75 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $63.08 | 2022-2025 | Ruconest |
| Ionis Pharmaceuticals, INC. | $44.55 | 2025 | Dawnzera |
| Bayer Healthcare Pharmaceuticals INC. | $41.49 | 2025 | |
| Adma Biomanufacturing LLC | $25.61 | 2025 | |
| Edwards Lifesciences Corporation | $24.41 | 2025 | |
| Incyte Corporation | $22.01 | 2023 | Opzelura |
| Galderma Laboratories, L.P. | $21.71 | 2025 | Nemluvio |
| Lilly USA, LLC | $18.47 | 2025 | Taltz |
| Corcept Therapeutics | $16.75 | 2024 | Korlym |
| Pfizer INC. | $15.03 | 2021 | |
| Hikma Pharmaceuticals USA | $14.55 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Dobrasz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.